TW200503729A - Treating androgen deficiency in female (ADIF)-associated conditions with SARMS - Google Patents

Treating androgen deficiency in female (ADIF)-associated conditions with SARMS

Info

Publication number
TW200503729A
TW200503729A TW093101758A TW93101758A TW200503729A TW 200503729 A TW200503729 A TW 200503729A TW 093101758 A TW093101758 A TW 093101758A TW 93101758 A TW93101758 A TW 93101758A TW 200503729 A TW200503729 A TW 200503729A
Authority
TW
Taiwan
Prior art keywords
female
adif
subject
treating
sarm
Prior art date
Application number
TW093101758A
Other languages
English (en)
Chinese (zh)
Inventor
James T Dalton
Duane D Miller
Mitchell S Steiner
Karen A Veverka
Original Assignee
Gtx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gtx Inc filed Critical Gtx Inc
Publication of TW200503729A publication Critical patent/TW200503729A/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26Androgens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW093101758A 2003-01-22 2004-01-27 Treating androgen deficiency in female (ADIF)-associated conditions with SARMS TW200503729A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44130803P 2003-01-22 2003-01-22

Publications (1)

Publication Number Publication Date
TW200503729A true TW200503729A (en) 2005-02-01

Family

ID=32771915

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093101758A TW200503729A (en) 2003-01-22 2004-01-27 Treating androgen deficiency in female (ADIF)-associated conditions with SARMS

Country Status (8)

Country Link
US (1) US20050032750A1 (enExample)
EP (1) EP1594490A4 (enExample)
JP (1) JP2006516286A (enExample)
CN (1) CN1771031A (enExample)
AU (1) AU2004206909A1 (enExample)
CA (1) CA2514024A1 (enExample)
TW (1) TW200503729A (enExample)
WO (1) WO2004064747A2 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7759520B2 (en) 1996-11-27 2010-07-20 University Of Tennessee Research Foundation Synthesis of selective androgen receptor modulators
US20040260108A1 (en) * 2001-06-25 2004-12-23 Dalton James T. Metabolites of selective androgen receptor modulators and methods of use thereof
US8445534B2 (en) 2000-08-24 2013-05-21 University Of Tennessee Research Foundation Treating androgen decline in aging male (ADAM)-associated conditions with SARMs
US20060276539A1 (en) * 2002-10-16 2006-12-07 Dalton James T Treating Androgen Decline in Aging Male (ADAM)- associated conditions with SARMS
WO2004035739A2 (en) * 2002-10-16 2004-04-29 Gtx, Inc. Treating androgen decline in aging male (adam)-associated conditions with sarms
US8309603B2 (en) 2004-06-07 2012-11-13 University Of Tennessee Research Foundation SARMs and method of use thereof
FI20030958A0 (fi) * 2003-06-27 2003-06-27 Orion Corp Uusia yhdisteitä
MXPA06002462A (es) * 2003-10-14 2006-06-20 Gtx Inc Tratamiento de desordenes relacionados con huesos con moduladores del receptor de angrogeno selectivo.
US9884038B2 (en) 2004-06-07 2018-02-06 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
US20090215731A1 (en) 2005-10-19 2009-08-27 Chavah Pty Ltd. Reduction of Side Effects From Aromatase Inhibitors Used for Treating Breast Cancer
KR100785038B1 (ko) * 2006-04-17 2007-12-12 삼성전자주식회사 비정질 ZnO계 TFT
CA2658394C (en) * 2006-07-12 2016-08-16 University Of Tennessee Research Foundation Substituted acylanilides and methods of use thereof
US9730908B2 (en) 2006-08-24 2017-08-15 University Of Tennessee Research Foundation SARMs and method of use thereof
US9844528B2 (en) 2006-08-24 2017-12-19 University Of Tennessee Research Foundation SARMs and method of use thereof
US10010521B2 (en) 2006-08-24 2018-07-03 University Of Tennessee Research Foundation SARMs and method of use thereof
PT2054049E (pt) 2006-08-24 2016-06-02 Univ Tennessee Res Found Acilanilidas substituídas e métodos de utilização das mesmas
US7968603B2 (en) 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
US8791158B2 (en) 2010-01-11 2014-07-29 Gtx, Inc. Methods of treating meibomian gland dysfunction
FR2982261B1 (fr) 2011-11-04 2014-06-13 Galderma Res & Dev Nouveaux amides, et leur utilisation pharmaceutique ou cosmetique
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
IN2015DN01046A (enExample) * 2012-07-13 2015-06-26 Gtx Inc
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
CN107405353B (zh) 2014-10-22 2021-07-30 哈瓦赫治疗有限公司 降低乳房摄影乳腺密度和/或乳腺癌风险的方法
SG11201803260PA (en) 2015-10-22 2018-05-30 Havah Therapeutics Pty Ltd Methods of reducing mammographic breast density and/or breast cancer risk
CN106405064B (zh) * 2016-08-30 2018-10-26 嘉兴行健生物科技有限公司 一种40岁以上女性骨转换率的评估方法
JP2022535827A (ja) 2019-06-03 2022-08-10 ハバ セラピューティクス ピーティワイ エルティディ アンドロゲン剤およびアロマターゼ阻害剤の送達のための医薬製剤およびシステム、ならびに使用のための方法
US11701332B2 (en) * 2020-11-18 2023-07-18 Bryce Nicholas Day Methods and compositions for treating female sexual interest and arousal disorder
WO2023101710A1 (en) * 2021-12-02 2023-06-08 Veru Inc. Methods of treating breast cancers with selective androgen receptor modulators and additional therapeutic agents
WO2025102293A1 (zh) * 2023-11-16 2025-05-22 北京脑科学与类脑研究所 神经活性雄激素受体调节剂及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8617653D0 (en) * 1986-07-18 1986-08-28 Ici Plc Amide derivatives
CA2132706C (en) * 1992-04-10 1998-08-04 John Eugene Macor Acylaminoindole derivatives as 5-ht1 agonists
US7026500B2 (en) * 2000-08-24 2006-04-11 University Of Tennessee Research Foundation Halogenated selective androgen receptor modulators and methods of use thereof
AU2001285230C1 (en) * 2000-08-24 2008-03-13 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
EA200401121A1 (ru) * 2002-02-28 2005-10-27 Юниверсити Оф Теннесси Рисерч Фаундейшн Необратимые селективные модуляторы андрогенового рецептора и способы их применения
BR0308176A (pt) * 2002-02-28 2005-01-04 Univ Tennessee Res Foundation Moduladores seletivos receptores de androgênio multi-substituìdos e seus métodos de uso
CN100537520C (zh) * 2002-06-17 2009-09-09 田纳西大学研究基金会 N-桥连选择性雄激素受体调节剂及其使用方法
AU2003287077B2 (en) * 2002-10-15 2007-09-20 University Of Tennessee Research Foundation Methylene-bridged selective androgen receptor modulators and methods of use thereof

Also Published As

Publication number Publication date
WO2004064747A3 (en) 2005-01-27
JP2006516286A (ja) 2006-06-29
AU2004206909A2 (en) 2004-08-05
WO2004064747A2 (en) 2004-08-05
CA2514024A1 (en) 2004-08-05
AU2004206909A1 (en) 2004-08-05
EP1594490A2 (en) 2005-11-16
CN1771031A (zh) 2006-05-10
EP1594490A4 (en) 2006-03-22
US20050032750A1 (en) 2005-02-10

Similar Documents

Publication Publication Date Title
TW200503729A (en) Treating androgen deficiency in female (ADIF)-associated conditions with SARMS
CA2538095A1 (en) Selective androgen receptor modulators and methods of use thereof
TW200407280A (en) N-bridged selective androgen receptor modulators and methods of use thereof
WO2004035737A3 (en) Heterocyclic selective androgen receptor modulators and methods of use thereof
WO2004035738A3 (en) Methylene-bridged selective androgen receptor modulators and methods of use thereof
EP1487458A4 (en) MULTI-SUBSTITUTED ANDROGEN SELECTIVE RECEPTOR MODULATORS AND METHODS AND USES THEREOF
WO2003074449A3 (en) Multi-substitued selective androgen receptor modulators and methods of use thereof
WO2005113565A3 (en) Metabolites of selective androgen receptor modulators and methods of use thereof
TW200502250A (en) Treating androgen decline in aging male (ADAM)-associated conditions with SARMS
WO2004062612A3 (en) Large-scale synthesis of selective androgen receptor modulators
WO2003074473A3 (en) Irreversible selective androgen receptor modulators and methods of use thereof
SI1902026T1 (sl) Derivati tetrahidrokarbazola uporabni kot modulatorji androgenskega receptorja
PL1891038T3 (pl) Podstawione n-arylopirolidyny jako selektywne modulatory receptora androgenowego
MX2011006790A (es) Composiciones para administracion de farmacos.
WO2009140448A8 (en) Tetrahydrocyclopenta[b]indole androgen receptor modulators
EP2656842A3 (en) Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
JO2800B1 (en) Rosaclubta tetrahydrate compounds [B] indole androgen regulators
WO2005037201A3 (en) Treating bone-related disorders with selective androgen receptor modulators
WO2007081696A3 (en) Treating androgen decline in aging male (adam)-associated conditions with sarms
TW200716662A (en) Process for making fluorinated 4-azasteroid derivatives
TW200512204A (en) A method of treating breast cancer with androgen receptor antagonists
WO2008110697A3 (fr) Utilisation d'un compose antagoniste des recepteurs nk2 de la neurokinine a pour la preparation de medicaments utiles pour la prevention et le traitement des dysfonctions sexuelles
EA200401123A1 (ru) Галогенацетамидные и азидзамещённые соединения и способы их применения